NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018

J Natl Compr Canc Netw. 2017 Oct;15(10):1193-1207. doi: 10.6004/jnccn.2017.0157.

Abstract

Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thrombohemorrhagic complications and a high risk of transformation to MF and acute myeloid leukemia. The diagnosis and management of PV and ET has evolved since the identification of mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss the recommendations outlined in the NCCN Guidelines for the risk stratification, treatment, and special considerations for the management of PV and ET.

Publication types

  • Practice Guideline

MeSH terms

  • Combined Modality Therapy / adverse effects
  • Combined Modality Therapy / methods
  • Humans
  • Myeloproliferative Disorders / diagnosis*
  • Myeloproliferative Disorders / therapy*
  • Risk Assessment
  • Treatment Outcome